Illinois Market Validates Brand Adoption
NEWTON, Mass., Nov. 06, 2017 (GLOBE NEWSWIRE) — MariMed Inc., (OTCQB:MRMD) today announced the near term expansion of its licensing of Kalm Fusion™ branded products. Test marketed with great success as previously announced in Delaware and Rhode Island, with a soft launch in 50 dispensaries in Illinois, MariMed is expanding licensing and distribution of its Kalm Fusion THC and CBD infused products into Nevada, Colorado, California, Oregon, Washington, Massachusetts and Maryland. MariMed is building a network of qualified, strategic licensed producers and distributors in these states that collectively service thousands of cannabis dispensaries. MariMed anticipates licensing revenue will ramp up in 2018 after licensing partners are announced later this quarter.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1845cfd6-b547-40fa-93de-b59559c61f84
Precisely dosed and all natural, Kalm Fusion’s marijuana-derived products include Mari Melts sublingual strips in multiple flavors, low dose Kalm Chewable Tablets, Kalm-Corn popcorn, and its new Powdered Tincture drink mix, all available in THC and CBD formulations. Designed to grab-and-go and discretely fit into daily life, Kalm Fusion products are develop under strict guidelines and manufacturing protocols. MariMed provides its Kalm Fusion licensees with manufacturing equipment, packaging and marketing support. MariMed does not provide finished goods, as it is up to each state licensee to manufacture and infuse THC and CBD to Kalm Fusion formulas.
“We developed and tested Kalm Fusion’s products over the past several years on thousands of patients,” said Tim Shaw, COO of MariMed. “Our patients’ repeated purchases have validated the demand for Kalm Fusion products for their consistent quality and effectiveness.”
MariMed partners with local growers and manufacturers in each state who meet Kalm Fusion’s strict standards: all natural— not artificial or synthetic — ingredients and locally grown by knowledgeable growers. Using deep knowledge of alchemy, chemistry and body science, Kalm Fusion products are scientifically formulated and custom designed for THC and CBD precise dosing and consistent results.
About Kalm Fusion
Kalm Fusion, a MariMed Inc., owned brand of all-natural cannabis products, is designed to make treatment a part of life that patients look forward to. Evoking “Kalm” as a lifestyle, the company aims to bring relief through enjoyable, reliable treatment and utmost respect to Mother Nature and body science. Kalm Fusion products are formulated with precision dosing for individual needs. Kalm Fusion products go through rigorous R & D and multiple layers of internal and third party laboratory testing to ensure consistency and precise dosing in product formulations. For more information on Kalm Fusion products, corporate social responsibility and licensing, visit www.KalmFusion.com
About MariMed Inc.:
MariMed Inc., collectively with its subsidiaries MariMed Advisors and Hartwell Realty, designs, develops, finances, and optimizes medical cannabis cultivation, production, and dispensary facilities as a management service. MariMed’s team has developed or is in the process of developing state-of-the art regulatory-compliant facilities in DE, IL, NV, MD, MA and RI. These facilities are models of excellence in horticultural principals, cannabis production, product development, and dispensary operations. MariMed is on the forefront of precision dosed products for the treatment of specific medical conditions. It currently distributes its branded products in select states and is expanding licensing and distribution to numerous additional states encompassing thousands of dispensaries. MariMed Inc., is one of the 17 top-performing public cannabis companies in the U.S. tracked on the U.S. Marijuana Index, (www.marijuanaindex.com). For more info visit www.MarimedAdvisors.com.
Forward Looking Statements:
This release contains certain forward-looking statements and information relating to MariMed Inc., that is based on the beliefs of MariMed Inc. management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events including estimates and projections about its business based on certain assumptions of its management, including those described in this Release. These statements are not guarantees of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company’s services and products, changes in the economic environment and changes in technology. Additional risk factors are included in the Company’s public filings with the SEC. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as “hoped,” “anticipated,” “believed,” “planned, “estimated,” “preparing,” “potential,” “expected” or words of a similar nature. The Company does not intend to update these forward-looking statements. None of the content of any of the websites of any other party referred to herein (even if a link is provided for your convenience) is incorporated into this release and the Company assumes no responsibility for any of such content.
Jon Levine, CFO, MariMed Advisors
Tyler Troup, Circadian Group
+1 (866) 950 8300
Julie Shepherd, Accentuate PR
Source: MariMed Inc.
Released November 6, 2017